Early ibuprofen treatment may not lower risk of death, bronchopulmonary dysplasia in preterm infants with PDA
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-01-29 05:00 GMT | Update On 2024-01-29 06:41 GMT
Advertisement
UK: Findings from the Baby-OSCAR trial revealed no evidence that early treatment with ibuprofen was associated with a lower risk of moderate or severe bronchopulmonary dysplasia or death than placebo at 36 weeks of postmenstrual age in extremely preterm infants with a large patent ductus arteriosus (PDA).
According to the study, published in The New England Journal of Medicine, Ibuprofen again failed to improve short-term outcomes when used to close PDA in newborns. The researchers argued that they at least found no evidence that ibuprofen caused serious complications.
Ibuprofen, administered parenterally a few days after infants were born prematurely, did not reduce the trial's combined primary endpoint nor its components at 36 weeks of postmenstrual age: Mortality and moderate or severe bronchopulmonary dysplasia: 69.2% vs 63.5% with placebo; mortality: 13.6% vs 10.3%; and moderate or severe bronchopulmonary dysplasia: 64.2% vs 59.3%.
The cyclooxygenase inhibitor ibuprofen ibuprofen may be used for treating PDA in preterm infants. However, it is unknown whether selective early treatment of large PDAs with ibuprofen would improve short-term outcomes. Samir Gupta, Sidra Medicine in Doha, Qatar, and colleagues aimed to evaluate early ibuprofen treatment (≤72 hours after birth) for a large patent ductus arteriosus (diameter of ≥1.5 mm with pulsatile flow) in extremely preterm infants (born between 23 weeks 0 days and 28 weeks 6 days’ gestation).
The study's primary outcome was a composite of death or moderate or severe bronchopulmonary dysplasia assessed at 36 weeks of postmenstrual age. A total of 326 infants were assigned to receive ibuprofen and 327 to receive placebo; 324 and 322, respectively, had data available for outcome analyses.
The study led to the following findings:
· A primary outcome event occurred in 69.2% of infants in the ibuprofen group and 63.5% of infants in the placebo group (adjusted risk ratio, 1.09).
· 13.6% of infants in the ibuprofen group and 10.3% of infants in the placebo group died (adjusted risk ratio, 1.32).
· Among the infants who survived to 36 weeks of postmenstrual age, moderate or severe bronchopulmonary dysplasia occurred in 64.2% in the ibuprofen group and 59.3% in the placebo group (adjusted risk ratio, 1.09).
· Two unforeseeable serious adverse events occurred that were possibly related to ibuprofen.
"We did not find a significantly lower risk of death or moderate or severe bronchopulmonary dysplasia at 36 weeks of postmenstrual age among infants who received early treatment with ibuprofen than among those who received a placebo," the researchers wrote.
Reference:
Gupta S, Subhedar NV, Bell JL, Field D, Bowler U, Hutchison E, Johnson S, Kelsall W, Pepperell J, Roberts T, Sinha S, Stanbury K, Wyllie J, Hardy P, Juszczak E; Baby-OSCAR Collaborative Group. Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen. N Engl J Med. 2024 Jan 25;390(4):314-325. doi: 10.1056/NEJMoa2305582. PMID: 38265644.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.